| EMA number | EMEA/H/C/000105 |
| ATC code | B01AD07 |
| Authorisation | 29 August 1996 |
| Withdrawn | 26 January 2024 |
| Revision | 28 |
Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.